Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875524 | 1.00 | MCHR1 (0.49) | MCHR1ADRA2ANPY5RSIGMAR1SLC6A4 | |
| SCHEMBL6873067 | 0.92 | MCHR1 (0.45) | MCHR1ADRA2ANPY5RSLC6A4BCHE | |
| SCHEMBL6873072 | 0.92 | MCHR1 (0.45) | MCHR1ADRA2ANPY5RSLC6A4BCHE | |
| SCHEMBL6878138 | 0.90 | MCHR1 (0.48) | MCHR1ADRA2ANPY5RSIGMAR1SLC6A4 | |
| SCHEMBL6878146 | 0.90 | MCHR1 (0.48) | MCHR1ADRA2ANPY5RSIGMAR1SLC6A4 | |
| SCHEMBL6878414 | 0.89 | TP53 (0.44) | MCHR1ADRA2ANPY5RSIGMAR1BCHE | |
| SCHEMBL6878418 | 0.89 | TP53 (0.44) | MCHR1ADRA2ANPY5RSIGMAR1BCHE | |
| SCHEMBL13796380 | 0.85 | MCHR1 (0.68) | MCHR1ADRA2ANPY5R | |
| SCHEMBL6874567 | 0.83 | MCHR1 (0.54) | MCHR1ADRA2ANPY5RBCHEACHE | |
| SCHEMBL6874559 | 0.83 | MCHR1 (0.54) | MCHR1ADRA2ANPY5RBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MCHR1 2/4885ADRA2A 117/4885NPY5R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.